(Miptenalimab)Biosimilar Reference Antibody-GS40437 新品

货号：GS40437

Miptenalimab is an IgG4-kappa monoclonal antibody developed by Boehringer Ingelheim that specifically targets lymphocyte activation gene 3 (LAG-3), an inhibitory immune checkpoint receptor. As an IgG4 isotype, it is engineered to minimize effector functions (e.g., ADCC) and focus on checkpoint blockade. By binding to LAG-3, it blocks its interaction with its primary ligand major histocompatibility complex class II (MHC-II), thereby reversing LAG-3-mediated inhibition of T-cell activation and function. This mechanism aims to restore and enhance anti-tumor immune responses. It is being developed as an immune checkpoint inhibitor for the treatment of advanced solid tumors.